pmcc logo sml

 

 

Here are the staff publications for June 2019.

Compiled by the Health Sciences Library (RMH, RWH, PMCC and Victorian Mental Health) 1st July 2019.

 

1. Alexander M, Sryjanen R, Ball D, MacManus M, Burbury K. The potential "additive" thromboembolic risk of radiotherapy. Asia-Pacific Journal of Clinical Oncology. 2019;15(3):183-4.

2. Allaway Z, Phillips RS, Thursky KA, Haeusler GM. Nonneutropenic fever in children with cancer: A scoping review of management and outcome. Pediatric Blood & Cancer. 2019;66(6):e27634.

3. Aslian H, Kron T, Longo F, Rad R, Severgnini M. A review and analysis of stereotactic body radiotherapy and radiosurgery of patients with cardiac implantable electronic devices. Australasian Physical & Engineering Sciences in Medicine. 2019;42(2):415-25.

4. Baguley BJ, Jefford M, Aly A, Cashin P, White V. Have centralised ethics and governance applications improved the time-variable, and approval process to conduct research in Victorian hospitals? Intern Med J. 2019;49(6):807-8.

5. Banting S, Milne D, Thorpe T, Na L, Spillane J, Speakman D, et al. Negative Sentinel Lymph Node Biopsy in Patients with Melanoma: The Patient's Perspective. Annals of Surgical Oncology. 2019;26(7):2263-7.

6. Bast RC, Jr., Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, et al. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer. 2019;125(12):1963-72.

7. Beard C, Purvis R, Winship IM, Macrae FA, Buchanan DD. Phenotypic confirmation of oligodontia, colorectal polyposis and cancer in a family carrying an exon 7 nonsense variant in the AXIN2 gene. Familial Cancer. 2019;18(3):311-5.

8. Beatty L, Kemp E, Coll JR, Turner J, Butow P, Milne D, et al. Finding My Way: results of a multicentre RCT evaluating a web-based self-guided psychosocial intervention for newly diagnosed cancer survivors. Supportive Care in Cancer. 2019;27(7):2533-44.

9. Bell CC, Fennell KA, Chan YC, Rambow F, Yeung MM, Vassiliadis D, et al. Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia. Nature Communications. 2019;10(1):2723.

10. Binkley MS, Brady JL, Hajj C, Chelius M, Chau K, Balogh A, et al. Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG. International Journal of Radiation Oncology, Biology, Physics. 2019;104(3):522-9.

11. Birkinshaw RW, Gong JN, Luo CS, Lio D, White CA, Anderson MA, et al. Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. Nature Communications. 2019;10(1):2385.

12. Blaschke SM, Schofield P, Taylor K, Ugalde A. Common dedication to facilitating good dying experiences: Qualitative study of end-of-life care professionals' attitudes towards voluntary assisted dying. Palliative Medicine. 2019;33(6):562-9.

13. Brandao RD, Mensaert K, Lopez-Perolio I, Tserpelis D, Xenakis M, Lattimore V, et al. Targeted RNA-seq successfully identifies normal and pathogenic splicing events in breast/ovarian cancer susceptibility and Lynch syndrome genes. International Journal of Cancer. 2019;145(2):401-14.

14. Cheasley D, Li N, Rowley SM, Elder K, Mann GB, Loi S, et al. Molecular comparison of interval and screen-detected breast cancers. Journal of Pathology. 2019;248(2):243-52.

15. Chew SM, Sweeney N, Kidd SE, Reed C. Candida auris arriving on our shores: an Australian microbiology laboratory's experience. Pathology. 2019;51(4):431-3.

16. Cloak K, Jameson MG, Paneghel A, Wiltshire K, Kneebone A, Pearse M, et al. Contour variation is a primary source of error when delivering post prostatectomy radiotherapy: Results of the Trans-Tasman Radiation Oncology Group 08.03 Radiotherapy Adjuvant Versus Early Salvage (RAVES) benchmarking exercise. Journal of Medical Imaging and Radiation Oncology. 2019;63(3):390-8.

17. Correa RJM, Louie AV, Staehler M, Warner A, Gandhidasan S, Ponsky L, et al. Stereotactic Radiotherapy as a Treatment Option for Renal Tumors in the Solitary Kidney: A Multicenter Analysis from the IROCK. Journal of Urology. 2019;201(6):1097-104.

18. Curchin DJ, Forward E, Dickison P, Harris VR, McCormack CJ, Smith SD. The acceleration of melanoma in situ: A population-based study of melanoma incidence trends from Victoria, Australia, 1985-2015. J Am Acad Dermatol. 2019;80(6):1791-3.

19. Deftereos I, Kiss N, Isenring E, Carter V, Yeung JMC. Letter to the Editors regarding: "Preoperative enteral access is not necessary prior to multimodality treatment of esophageal cancer". Surgery. 2019;166(1):126-7.

20. Dendle C, Polkinghorne KR, Mulley WR, Gan PY, Kanellis J, Stuart RL, et al. A simple score can identify kidney transplant recipients at high risk of severe infection over the following 2 years. Transplant Infectious Disease. 2019;21(3):e13076.

21. Doyle J, Raggatt M, Slavin M, McLachlan SA, Strasser SI, Sasadeusz JJ, et al. Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement. Medical Journal of Australia. 2019;210(10):462-8.

22. Duncan C, Omran GJ, Teh J, Davis NF, Bolton DM, Lawrentschuk N. Erectile dysfunction: a global review of intracavernosal injectables. World Journal of Urology. 2019;37(6):1007-14.

23. Emmett L, Metser U, Bauman G, Hicks RJ, Weickhardt A, Davis ID, et al. Prospective, Multisite, International Comparison of (18)F-Fluoromethylcholine PET/CT, Multiparametric MRI, and (68)Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes. Journal of Nuclear Medicine. 2019;60(6):794-800.

24. Fallmann J, Videm P, Bagnacani A, Batut B, Doyle MA, Klingstrom T, et al. The RNA workbench 2.0: next generation RNA data analysis. Nucleic Acids Res. 2019;47(W1):W511-w5.

25. Farshid G, Bilous M, Morey A, Fox S, Lakhani S, Loi S, et al. ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia. Pathology. 2019;51(4):345-8.

26. Foroughi S, Wong HL, Gately L, Lee M, Simons K, Tie J, et al. Registry-based randomized clinical trials as a method to improve cancer care in Australia. Asia-Pacific Journal of Clinical Oncology. 2019;15(3):188-9.

27. Fortuno C, Cipponi A, Ballinger ML, Tavtigian SV, Olivier M, Ruparel V, et al. A quantitative model to predict pathogenicity of missense variants in the TP53 gene. Human Mutation. 2019;40(6):788-800.

28. Frowen J. Dysphagia in patients with non-head and neck cancer. Current opinion in otolaryngology & head and neck surgery. 2019;27(3):162-7.

29. Gargett M, Haddad C, Kneebone A, Booth JT, Hardcastle N. Clinical impact of removing respiratory motion during liver SABR. Radiation Oncology. 2019;14(1):93.

30. Hamadi A, Grigg AP, Dobie G, Burbury KL, Schwarer AP, Kwa FA, et al. Ponatinib Tyrosine Kinase Inhibitor Induces a Thromboinflammatory Response. Thrombosis and haemostasis. 2019;119(7):1112-23.

31. Hicks RJ, Jackson P, Kong G, Ware RE, Hofman MS, Pattison DA, et al. (64)Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy. Journal of Nuclear Medicine. 2019;60(6):777-85.

32. Hunter D, Wright C, Pearson S. Employing positive psychology to improve radiation therapy workplace culture. Journal of Medical Radiation Sciences. 2019;66(2):139-44.

33. Jackson JE, Anderson NJ, Rolfo M, Wada M, Schneider M, Poulsen M, et al. (18)F-FDG Metabolic Tumor Volume: Association with Short- and Long-Term Feeding Tube Use in Head and Neck IMRT. Dysphagia. 2019;34(3):341-9.

34. Jamois C, Gibiansky E, Gibiansky L, Buchheit V, Sahin D, Cartron G, et al. Role of obinutuzumab exposure on clinical outcome of follicular lymphoma treated with first-line immunochemotherapy. British Journal of Clinical Pharmacology. 2019;85(7):1495-506.

35. Jones JRA, Berney S, Connolly B, Waterland JL, Denehy L, Griffith DM, et al. Socioeconomic Position and Health Outcomes Following Critical Illness: A Systematic Review. Critical Care Medicine. 2019;47(6):e512-e21.

36. Kader T, Hill P, Zethoven M, Goode DL, Elder K, Thio N, et al. Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma. Journal of Pathology. 2019;248(3):326-38.

37. Kelleher FC, Kroes J, Lewin J. Targeting the centrosome and polo-like kinase 4 in osteosarcoma. Carcinogenesis. 2019;40(4):493-9.

38. Kerage D, Sloan EK, Mattarollo SR, McCombe PA. Interaction of neurotransmitters and neurochemicals with lymphocytes. Journal of neuroimmunology. 2019;332:99-111.

39. Kilpatrick LE, Alcobia DC, White CW, Peach CJ, Glenn JR, Zimmerman K, et al. Complex Formation between VEGFR2 and the beta2-Adrenoceptor. Cell chemical biology. 2019;26(6):830-41.e9.

40. Kiss N, Beraldo J, Everitt S. Early Skeletal Muscle Loss in Non-Small Cell Lung Cancer Patients Receiving Chemoradiation and Relationship to Survival. Supportive Care in Cancer. 2019;27(7):2657-64.

41. Kron T, Krishnan P. Leonardo DaVinci's contributions to medical physics and biomedical engineering: celebrating the life of a 'Polymath'. Australasian Physical & Engineering Sciences in Medicine. 2019;42(2):403-5.

42. Lasica M, Willcox A, Burbury K, Ross DM, Branford S, Butler J, et al. The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia. Leuk Lymphoma. 2019;60(7):1796-802.

43. Lawrentschuk N. Editorial Comment. Journal of Urology. 2019;201(6):1104.

44. Le Roux PY, Iravani A, Callahan J, Burbury K, Eu P, Steinfort DP, et al. Independent and incremental value of ventilation/perfusion PET/CT and CT pulmonary angiography for pulmonary embolism diagnosis: results of the PECAN pilot study. European Journal of Nuclear Medicine and Molecular Imaging. 2019;46(8):1596-604.

45. Leitinger E, Hui L, Grigg A. Is there a role for proton pump inhibitor prophylaxis in haematology patients? Intern Med J. 2019;49(6):694-701.

46. Lippey J, Keogh LA, Mann GB, Campbell IG, Forrest LE. "A Natural Progression": Australian Women's Attitudes About an Individualized Breast Screening Model. Cancer Prevention Research (Philadelphia). 2019;12(6):383-90.

47. Loftus MJ, Yong MK, Wilson S, Peleg AY. Fatal disseminated visceral varicella zoster virus infection in a renal transplant recipient. Transplant Infectious Disease. 2019;21(3):e13062.

48. Lopez-Perolio I, Leman R, Behar R, Lattimore V, Pearson JF, Castera L, et al. Alternative splicing and ACMG-AMP-2015-based classification of PALB2 genetic variants: an ENIGMA report. Journal of Medical Genetics. 2019;56(7):453-60.

49. Mardiana S, Solomon BJ, Darcy PK, Beavis PA. Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression. Science Ttranslational Medicine. 2019;11(495).

50. Mileshkin L, Edmondson R, O'Connell RL, Sjoquist KM, Andrews J, Jyothirmayi R, et al. Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903. Gynecol Oncol. 2019;154(1):29-37.

51. Mitchell ML, Shafee T, Papenfuss AT, Norton RS. Evolution of cnidarian trans-defensins: Sequence, structure and exploration of chemical space. Proteins. 2019;87(7):551-60.

52. Morrow A, Hogden E, Kang YJ, Steinberg J, Canfell K, Solomon MJ, et al. Comparing theory and non-theory based implementation approaches to improving referral practices in cancer genetics: a cluster randomised trial protocol. Trials. 2019;20(1):373.

53. Murphy DG, Azad AA, Sandhu S, Violet J, Hofman MS. Prostate-specific Membrane Antigen Across the Spectrum of Prostate Cancer: Detection, Surgery, and Theranostics. European Urology. 2019;75(6):927-8.

54. Nan Tie E, Henderson MA, Gyorki DE. Management of in-transit melanoma metastases: a review. ANZ J Surg. 2019;89(6):647-52.

55. Parente P, Chan BA, Hughes BGM, Jasas K, Joshi R, Kao S, et al. Patterns of care for stage III non-small cell lung cancer in Australia. Asia-Pacific Journal of Clinical Oncology. 2019;15(3):93-100.

56. Pires da Silva I, Glitza IC, Haydu LE, Johnpulle R, Banks PD, Grass GD, et al. Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. Pigment Cell & Melanoma Research. 2019;32(4):553-63.

57. Porter LH, Lawrence MG, Wang H, Clark AK, Bakshi A, Obinata D, et al. Establishing a cryopreservation protocol for patient-derived xenografts of prostate cancer. Prostate. 2019;79(11):1326-37.

58. Remon J, Ahn MJ, Girard N, Johnson M, Kim DW, Lopes G, et al. Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018. Journal of Thoracic Oncology. 2019;14(7):1134-55.

59. Reynolds HM, Williams S, Jackson P, Mitchell C, Hofman MS, Hicks RJ, et al. Voxel-wise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework. BJU International. 2019;123(6):1020-30.

60. Rothe F, Silva MJ, Venet D, Campbell C, Bradburry I, Rouas G, et al. Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial. Clinical Cancer Research. 2019;25(12):3581-8.

61. Russell L, Ugalde A, Orellana L, Milne D, Krishnasamy M, Chambers R, et al. A pilot randomised controlled trial of an online mindfulness-based program for people diagnosed with melanoma. Supportive Care in Cancer. 2019;27(7):2735-46.

62. Saner FAM, Herschtal A, Nelson BH, deFazio A, Goode EL, Ramus SJ, et al. Going to extremes: determinants of extraordinary response and survival in patients with cancer. Nature Reviews: Cancer. 2019;19(6):339-48.

63. Sathianathen NJ, Konety BR, Alarid-Escudero F, Lawrentschuk N, Bolton DM, Kuntz KM. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer. European Urology. 2019;75(6):910-7.

64. Schofield P, Shaw T, Pascoe M. Toward Comprehensive Patient-Centric Care by Integrating Digital Health Technology With Direct Clinical Contact in Australia. Journal of medical Internet research. 2019;21(6):e12382.

65. Seymour JF, Marcus R, Davies A, Gallop-Evans E, Grigg A, Haynes A, et al. Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica. 2019;104(6):1202-8.

66. Shaw AT, Solomon BJ, Besse B, Bauer TM, Lin CC, Soo RA, et al. ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. Journal of Clinical Oncology. 2019;37(16):1370-9.

67. Soumerai JD, Ni A, Darif M, Londhe A, Xing G, Mun Y, et al. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. Lancet: Haematology. 2019;6(7):e366-e74.

68. Stansook N, Biasi G, Utitsarn K, Petasecca M, Metcalfe P, Carolan M, et al. 2D monolithic silicon-diode array detectors in megavoltage photon beams: does the fabrication technology matter? A medical physicist's perspective. Australasian Physical & Engineering Sciences in Medicine. 2019;42(2):443-51.

69. Steiner E, Shieh CC, Caillet V, Booth J, O'Brien R, Briggs A, et al. Both four-dimensional computed tomography and four-dimensional cone beam computed tomography under-predict lung target motion during radiotherapy. Radiotherapy and Oncology. 2019;135:65-73.

70. Teh BW, Chui W, Handunnetti S, Tam C, Worth LJ, Thursky KA, et al. High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2019;60(6):1572-5.

71. Teh J, Narasimhan V, Schultz S, Sathianathen N, Murphy DG. Re: Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. European Urology. 2019;76(1):126-7.

72. Teh J, Wei J, Chiang G, Nzenza TC, Bolton D, Lawrentschuk N. Men's health on the web: an analysis of current resources. World Journal of Urology. 2019;37(6):1043-7.

73. Tew M, Clarke P, Thursky K, Dalziel K. Incorporating Future Medical Costs: Impact on Cost-Effectiveness Analysis in Cancer Patients. PharmacoEconomics. 2019;37(7):931-41.

74. Toivanen R, Furic L. A balancing act: PHLPP2 fine tunes AKT activity and MYC stability in prostate cancer. Journal of Cell Biology. 2019;218(6):1771-2.

75. Toss MS, Miligy IM, Haj-Ahmad R, Gorringe KL, AlKawaz A, Mittal K, et al. The prognostic significance of lysosomal protective protein (cathepsin A) in breast ductal carcinoma in situ. Histopathology. 2019;74(7):1025-35.

76. Van Cutsem E, Huijberts S, Grothey A, Yaeger R, Cuyle PJ, Elez E, et al. Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study. Journal of Clinical Oncology. 2019;37(17):1460-9.

77. Ware RE, Williams S, Hicks RJ. Molecular Imaging of Recurrent and Metastatic Prostate Cancer. Seminars in Nuclear Medicine. 2019;49(4):280-93.

78. White VM, Orme LM, Skaczkowski G, Pinkerton R, Coory M, Osborn M, et al. Management of Sarcoma in Adolescents and Young Adults: An Australian Population-Based Study. Journal of Adolescent and Young Adult Oncology. 2019;8(3):272-80.

79. Wiede F, Brodnicki TC, Goh PK, Leong YA, Jones GW, Yu D, et al. T-Cell-Specific PTPN2 Deficiency in NOD Mice Accelerates the Development of Type 1 Diabetes and Autoimmune Comorbidities. Diabetes. 2019;68(6):1251-66.

80. Wierda WG, Byrd JC, O'Brien S, Coutre S, Barr PM, Furman RR, et al. Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. Br J Haematol. 2019;186(1):184-8.

81. Wong R, Tie J, Lee M, Cohen J, Wang Y, Li L, et al. The potential role of circulating tumor DNA (ctDNA) in the further investigation of colorectal cancer patients with nonspecific findings on standard investigations. International Journal of Cancer. 2019;145(2):540-7.

82. Xing D, Siva S, Hanna GG. The Abscopal Effect of Stereotactic Radiotherapy and Immunotherapy: Fool's Gold or El Dorado? Clinical Oncology (Royal College of Radiologists). 2019;31(7):432-43.

83. Yan Y, Wongchenko MJ, Robert C, Larkin J, Ascierto PA, Dreno B, et al. Genomic Features of Exceptional Response in Vemurafenib +/- Cobimetinib-treated Patients with BRAF (V600)-mutated Metastatic Melanoma. Clinical Cancer Research. 2019;25(11):3239-46.

84. Young R, Norris B, Reeves F, Peters JS. A Retrospective Comparison of Transrectal and Transperineal Prostate Biopsies: Experience of a Single Surgeon. Journal of Endourology. 2019;33(6):498-502.

85. Zeinomar N, Phillips KA, Daly MB, Milne RL, Dite GS, MacInnis RJ, et al. Benign breast disease increases breast cancer risk independent of underlying familial risk profile: Findings from a Prospective Family Study Cohort. International Journal of Cancer. 2019;145(2):370-9.